Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses

Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-...

Descripción completa

Detalles Bibliográficos
Autores principales: Gridelli, C, Frontini, L, Perrone, F, Gallo, C, Gulisano, M, Cigolari, S, Castiglione, F, Robbiati, S F, Gasparini, G, Ianniello, G P, Farris, A, Locatelli, M C, Felletti, R, Piazza, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://www.ncbi.nlm.nih.gov/pubmed/10952772
http://dx.doi.org/10.1054/bjoc.2000.1341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363528/
https://www.ncbi.nlm.nih.gov/pubmed/10952772
http://dx.doi.org/10.1054/bjoc.2000.1341

Ejemplares similares